Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This is a multicenter, randomised, four arms placebo controlled study to evaluate the safety and tolerability of 10 mg inhaled zanamivir once a day and 75 mg oseltamivir capsule orally once a day relative to placebo over 16 weeks (112 days). Enrolled subjects will be randomly assigned to 2:1:2:1 ratio (active oseltamivir: placebo: active zanamivir: placebo) on one of the four study treatment groups. It is hypothesized that oseltamivir and zanamivir will protect participants from becoming infected with influenza.
Epistemonikos ID: 88d9720c67f6d103a06b0145e7bd1a29ff5c9c28
First added on: May 05, 2024